• Divestment includes Xiidra^®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies
• Novartis advances strategy of focused portfolio and prioritized therapeutic areas for future growth

Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potential add